{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:54:40Z","timestamp":1788998080581,"version":"build-2803163510"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ctrv.2026.103141","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T06:51:53Z","timestamp":1776927113000},"page":"103141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Targeting claudins in gastric cancer: A novel GLOWing strategy in the SPOTLIGHT"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3203-8682","authenticated-orcid":false,"given":"Mario","family":"Balsa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bug\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Layos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariona","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisenda","family":"Garsot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Viciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantxa","family":"Clavell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Uchima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Muriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Mirallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariela Blum","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Ter\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Montal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Fleitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-2172","authenticated-orcid":false,"given":"Cinta","family":"Hierro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ctrv.2026.103141_b0005","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Intl Journal of Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103141_b0010","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41575-022-00703-w","article-title":"Current developments in gastric cancer: from molecular profiling to treatment strategy","volume":"20","author":"Alsina","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9742","key":"10.1016\/j.ctrv.2026.103141_b0015","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"10418","key":"10.1016\/j.ctrv.2026.103141_b0020","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.ctrv.2026.103141_b0025","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab Deruxtecan in previously Treated HER2-positive Gastric Cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103141_b0030","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"Van Cutsem","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103141_b0035","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"issue":"10294","key":"10.1016\/j.ctrv.2026.103141_b0040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103141_b0045","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103141_b0050","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103141_b0055","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat Med"},{"issue":"55","key":"10.1016\/j.ctrv.2026.103141_b0060","doi-asserted-by":"crossref","first-page":"6930","DOI":"10.1038\/onc.2008.344","article-title":"Tight junction-based epithelial microenvironment and cell proliferation","volume":"27","author":"Tsukita","year":"2008","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103141_b0065","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.bbamem.2007.08.018","article-title":"Crosstalk of tight junction components with signaling pathways","volume":"1778","author":"Gonz\u00e1lez-Mariscal","year":"2008","journal-title":"Biochim Biophys Acta Biomembr"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103141_b0070","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.bbamem.2007.10.018","article-title":"Structure and function of claudins","volume":"1778","author":"Krause","year":"2008","journal-title":"Biochim Biophys Acta Biomembr"},{"issue":"45","key":"10.1016\/j.ctrv.2026.103141_b0075","doi-asserted-by":"crossref","first-page":"29745","DOI":"10.1074\/jbc.273.45.29745","article-title":"The Tight Junction Protein ZO-1 Establishes a link between the Transmembrane Protein Occludin and the Actin Cytoskeleton","volume":"273","author":"Fanning","year":"1998","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103141_b0080","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrm.2016.80","article-title":"Tight junctions: from simple barriers to multifunctional molecular gates","volume":"17","author":"Zihni","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103141_b0085","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/onc.2011.216","article-title":"Opposing roles of angiomotin-like-1 and zona occludens-2 on pro-apoptotic function of YAP","volume":"31","author":"Oka","year":"2012","journal-title":"Oncogene"},{"issue":"47","key":"10.1016\/j.ctrv.2026.103141_b0090","doi-asserted-by":"crossref","first-page":"7405","DOI":"10.3748\/wjg.v11.i47.7405","article-title":"Gene expression profiling of gastric cancer by microarray combined with laser capture microdissection","volume":"11","author":"Wu","year":"2005","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103141_b0095","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1152\/physrev.00019.2012","article-title":"Claudins and the Modulation of Tight Junction Permeability","volume":"93","author":"G\u00fcnzel","year":"2013","journal-title":"Physiol Rev"},{"issue":"24","key":"10.1016\/j.ctrv.2026.103141_b0100","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.1242\/jcs.00165","article-title":"Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells","volume":"115","author":"Amasheh","year":"2002","journal-title":"J Cell Sci"},{"key":"10.1016\/j.ctrv.2026.103141_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1494131","article-title":"Pan-cancer analysis of CLDN18.2 shed new insights on the targeted therapy of upper gastrointestinal tract cancers","volume":"15","author":"Wu","year":"2024","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103141_b0110","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3892\/ijmm.2024.5424","article-title":"Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (Review)","volume":"54","author":"Katoh","year":"2024","journal-title":"Int J Mol Med"},{"issue":"21","key":"10.1016\/j.ctrv.2026.103141_b0115","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1128\/MCB.21.21.7380-7390.2001","article-title":"claudin-18 , a Novel Downstream Target Gene for the T\/EBP\/NKX2.1 Homeodomain Transcription factor, Encodes Lung- and Stomach-specific Isoforms through Alternative Splicin","volume":"21","author":"Niimi","year":"2001","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2026.103141_b0120","doi-asserted-by":"crossref","unstructured":"Hong JY, An JY, Lee J, Park SH, Park JO, Park YS, et al. Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer. Transl Cancer Res. 2020. 9(5):3367\u201374. doi:10.21037\/tcr-19-1876 PubMed PMID: 35117702; PubMed Central PMCID: PMC8797704.","DOI":"10.21037\/tcr-19-1876"},{"issue":"23","key":"10.1016\/j.ctrv.2026.103141_b0125","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 Splice Variant 2 is a Pan-Cancer Target Suitable for Therapeutic Antibody Development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103141_b0130","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1074\/jbc.275.8.5773","article-title":"Occludin Modulates Transepithelial Migration of Neutrophils","volume":"275","author":"Huber","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2026.103141_b0135","unstructured":"Tight junctions and their role in cancer metastasis. Histology and Histopathology. 2001. (16):1183\u201395. doi:10.14670\/HH-16.1183."},{"issue":"5","key":"10.1016\/j.ctrv.2026.103141_b0140","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","article-title":"Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma","volume":"27","author":"Shitara","year":"2024","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ctrv.2026.103141_b0145","doi-asserted-by":"crossref","unstructured":"Ungureanu BS, Lungulescu CV, Pirici D, Turcu-Stiolica A, Gheonea DI, Sacerdotianu VM, et al. Clinicopathologic Relevance of Claudin 18.2 Expression in Gastric Cancer: A Meta-Analysis. Front Oncol. 2021;11:643872. doi:10.3389\/fonc.2021.643872 PubMed PMID: 33747967; PubMed Central PMCID: PMC7969651.","DOI":"10.3389\/fonc.2021.643872"},{"key":"10.1016\/j.ctrv.2026.103141_b0150","doi-asserted-by":"crossref","unstructured":"Kubota Y, Kawazoe A, Mishima S, Nakamura Y, Kotani D, Kuboki Y, et al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open. 2023. 8(1):100762. doi:10.1016\/j.esmoop.2022.100762 PubMed PMID: 36610262; PubMed Central PMCID: PMC10024138.","DOI":"10.1016\/j.esmoop.2022.100762"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103141_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.106053","article-title":"Claudin 18.2 expression in gastroesophageal adenocarcinoma: biomarker overlap and association with clinical outcomes in a European cohort","volume":"11","author":"Ter\u00e1n","year":"2026","journal-title":"ESMO Open"},{"issue":"7517","key":"10.1016\/j.ctrv.2026.103141_b0160","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"issue":"10389","key":"10.1016\/j.ctrv.2026.103141_b0165","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103141_b0170","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103141_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100589","article-title":"Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: a Practical Approach","volume":"37","author":"Fassan","year":"2024","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2026.103141_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155145","article-title":"Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: a literature review with expert opinion","volume":"254","author":"Angerilli","year":"2024","journal-title":"Pathology - Research and Practice"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103141_b0185","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/cncy.22688","article-title":"Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: acomparative study with tissue specimens","volume":"131","author":"Dai","year":"2023","journal-title":"Cancer Cytopathol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103141_b0190","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/cas.70100","article-title":"Landscape Analysis of CLDN18 Expression and Isoform distribution in Solid Tumors: Insights from MONSTAR \u2010 SCREEN \u20102 Study","volume":"116","author":"Hashimoto","year":"2025","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2026.103141_b0195","doi-asserted-by":"crossref","unstructured":"Martinez-Ciarpaglini C, Ortega M, P\u00e9rez-Buira S, Bolea A, Casado Guerra B, Herencia Bellido C, et al. CLDN18.2 expression in gastroesophageal adenocarcinoma: prevalence, heterogeneity, and prognostic implications in Spanish patients. Virchows Arch. 2025. 487(6):1337\u201346. doi:10.1007\/s00428-025-04247-7 PubMed PMID: 41206380; PubMed Central PMCID: PMC12748129.","DOI":"10.1007\/s00428-025-04247-7"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103141_b0200","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/jjco\/hyz068","article-title":"Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma","volume":"49","author":"Rohde","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103141_b0205","article-title":"Temporal dynamics of CLDN18.2 expression following zolbetuximab treatment in advanced gastric cancer. ESMO","volume":"9","author":"Yamamoto","year":"2025","journal-title":"Gastrointest Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103141_b0210","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","article-title":"FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma","volume":"32","author":"Sahin","year":"2021","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103141_b0215","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1056\/NEJMc2409512","article-title":"Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma","volume":"391","author":"Shitara","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103141_b0220","unstructured":"U.S. Food and Drug Administration. Approval Letter: Zolbetuximab-clzb (BLA 761365) [Internet]. Silver Spring (MD): U.S. Food and Drug Administration. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/761365Orig1s000Approv.pdf."},{"key":"10.1016\/j.ctrv.2026.103141_b0225","series-title":"Review Report: VYLOY\u00ae (zolbetuximab) for the treatment of gastric cancer [internet]","author":"Pharmaceuticals and Medical Devices Agency","year":"2024"},{"key":"10.1016\/j.ctrv.2026.103141_b0230","series-title":"VYLOY (zolbetuximab): European Public Assessment Report (EPAR) \u2013 Assessment Report [internet]","author":"European Medicines Agency","year":"2024"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103141_b0235","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s10120-024-01566-7","article-title":"Survival outcomes of patients with gastric cancer treated with first-line nivolumab plus chemotherapy based on claudin 18.2 expression","volume":"28","author":"Kim","year":"2025","journal-title":"Gastric Cancer"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103141_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104000","article-title":"Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer","volume":"9","author":"Kim","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103141_b0245","article-title":"Impact of claudin 18.2 expression on treatment outcomes of first-line immunochemotherapy in patients with HER2-negative, proficient MMR, PD-L1 CPS \u2a7e1 metastatic gastric\/gastroesophageal junction cancer. Ther Adv","volume":"17","author":"Zhang","year":"2025","journal-title":"Med Oncol"},{"key":"10.1016\/j.ctrv.2026.103141_b0250","article-title":"Phase 2 trial of zolbetuximab in combination with mFOLFOX6 and nivolumab in patients with advanced or metastatic claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas","volume":"41(16_suppl):TPS4173\u2013TPS4173","author":"Shitara","year":"2023","journal-title":"JCO"},{"issue":"19","key":"10.1016\/j.ctrv.2026.103141_b0255","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1158\/1078-0432.CCR-23-0204","article-title":"ILUSTRO: phase II Multicohort Trial of Zolbetuximab in patients with Advanced or Metastatic Claudin 18.2\u2013Positive Gastric or Gastroesophageal Junction Adenocarcinoma","volume":"29","author":"Klempner","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103141_b0260","first-page":"16","article-title":"First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial","author":"Shitara","year":"2026","journal-title":"Nat Med"},{"issue":"2_suppl","key":"10.1016\/j.ctrv.2026.103141_b0265","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.2_suppl.TPS473","article-title":"Zolbetuximab + pembrolizumab and chemotherapy as first-line treatment for patients with CLDN18.2-positive, HER2-negative, PD-L1-positive locally advanced unresectable or metastatic G\/GEJ adenocarcinoma: phase 3, double-blind, randomized trial (LUCERNA)","volume":"44","author":"Shitara","year":"2026","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103141_b0270","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1038\/s41591-025-03781-w","article-title":"The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial","volume":"31","author":"Ruan","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103141_b0275","article-title":"A phase 1 trial of claudin 18.2-specific antibody-drug conjugate CMG901 in patients with advanced gastric\/gastroesophageal junction cancer","volume":"41(36_suppl):434420\u2013434420","author":"Xu","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2026.103141_b0280","article-title":"First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant\/refractory solid tumors","volume":"41(16_suppl):3016\u20133016","author":"Wang","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2026.103141_b0285","article-title":"Efficacy and safety of LM-302 (anti-claudin 18.2 ADC) in combination with anti-PD-1 therapy for advanced gastric, gastroesophageal junction cancer and esophageal adenocarcinoma: Early-phase study results","volume":"43(16_suppl):4039\u20134039","author":"Jiang","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2026.103141_b0290","doi-asserted-by":"crossref","unstructured":"Liu J, Yang J, Sun Y, Gong J, Yue J, Pan Y, et al. CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial. Nat Med. 2025. 31(9):3028\u201336. doi:10.1038\/s41591-025-03783-8 PubMed PMID: 40670773; PubMed Central PMCID: PMC12443601.","DOI":"10.1038\/s41591-025-03783-8"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103141_b0295","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s12325-017-0519-6","article-title":"Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: a Review","volume":"34","author":"Lambert","year":"2017","journal-title":"Adv Ther"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103141_b0300","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat Med"},{"issue":"10494","key":"10.1016\/j.ctrv.2026.103141_b0305","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103141_b0310","doi-asserted-by":"crossref","unstructured":"Ku G, Shen L, Dayyani F, Kratz J, Liang X, Liu F, et al. A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2025. 31(23):4944\u201352. doi:10.1158\/1078-0432.CCR-24-4280 PubMed PMID: 40586719; PubMed Central PMCID: PMC12582174.","DOI":"10.1158\/1078-0432.CCR-24-4280"},{"key":"10.1016\/j.ctrv.2026.103141_b0315","article-title":"First-in-human phase I\/II safety and preliminary efficacy of PM1032, a bispecific antibody targeting CLDN18.2 and 4-1BB, in patients with advanced solid tumors","volume":"42(16_suppl):2662\u20132662","author":"Guo","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2026.103141_b0320","article-title":"Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2\/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study","volume":"42(16_suppl):2519\u20132519","author":"Zheng","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2026.103141_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114075","article-title":"Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review","volume":"205","author":"G\u00e9raud","year":"2024","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103141_b0330","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s12276-023-01136-4","article-title":"4-1BB immunotherapy: advances and hurdles","volume":"56","author":"Singh","year":"2024","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.ctrv.2026.103141_b0335","article-title":"Enhancing antitumor efficacy of CLDN18.2-directed antibody-drug conjugates through autophagy inhibition in gastric cancer","volume":"10(1):393","author":"Xue","year":"2024","journal-title":"Cell Death Discov"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103141_b0340","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41419-024-06665-y","article-title":"A potential strategy for bladder cancer treatment: inhibiting autophagy to enhance antitumor effects of Nectin-4-MMAE","volume":"15","author":"Wang","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ctrv.2026.103141_b0345","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.3389\/fimmu.2018.01799","article-title":"Activating Autophagy Enhanced the Antitumor effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E","volume":"9","author":"Wang","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2026.103141_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217285","article-title":"Autophagy and cancer therapy","volume":"605","author":"Pimentel","year":"2024","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103141_b0355","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/s12967-023-04433-8","article-title":"The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis","volume":"21","author":"Simon","year":"2023","journal-title":"J Transl Med"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103141_b0360","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3233\/CBM-201554","article-title":"Claudin-6 is down-regulated in gastric cancer and its potential pathway","volume":"28","author":"Lu","year":"2020","journal-title":"CBM"},{"issue":"24","key":"10.1016\/j.ctrv.2026.103141_b0365","doi-asserted-by":"crossref","first-page":"13416","DOI":"10.3390\/ijms222413416","article-title":"CLDN6: from Traditional Barrier Function to Emerging Roles in Cancers","volume":"22","author":"Qu","year":"2021","journal-title":"IJMS"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103141_b0370","doi-asserted-by":"crossref","first-page":"13977","DOI":"10.3390\/ijms232213977","article-title":"Chromosomally Unstable Gastric Cancers Overexpressing Claudin-6 Disclose Cross-talk between HNF1A and HNF4A, and Upregulated Cholesterol Metabolism","volume":"23","author":"Dwivedi","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103141_b0375","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41419-019-2168-y","article-title":"CLDN6 promotes tumor progression through the YAP1-snail1 axis in gastric cancer","volume":"10","author":"Yu","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ctrv.2026.103141_b0380","article-title":"Expression of CLDN6 in tissues of gastric cancer patients: Association with clinical pathology and prognosis","author":"Gao","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ctrv.2026.103141_b0385","unstructured":"NJ Tokyo, Basking Ridge. DS-9606 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors [Internet]. Available from: https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202409\/20240915_E.pdf."},{"key":"10.1016\/j.ctrv.2026.103141_b0390","doi-asserted-by":"crossref","first-page":"S488","DOI":"10.1016\/j.annonc.2024.08.677","article-title":"610O Preliminary results from a phase I, first-in-human study of DS-9606a, a claudin 6 (CLDN6)-directed antibody-drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6","volume":"35","author":"Patel","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103141_b0395","doi-asserted-by":"crossref","first-page":"S489","DOI":"10.1016\/j.annonc.2024.08.678","article-title":"611O Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed\/refractory CLDN6+ solid tumors","volume":"35","author":"Haanen","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103141_b0400","article-title":"First-in-human phase I\/II trial evaluating BNT142, a first-in-class mRNA encoded, bispecific antibody targeting Claudin 6 (CLDN6) and CD3, in patients (pts) with CLDN6-positive advanced solid tumors","volume":"43(16_suppl):2501\u20132501","author":"Yap","year":"2025","journal-title":"JCO"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2026.103141_b0405","article-title":"A phase 1, first-in-human study of CTIM-76, a claudin-6 (CLDN6)-directed bispecific antibody, in patients with recurrent ovarian cancer and other advanced solid tumors","volume":"43","author":"O\u2019Cearbhaill","year":"2025","journal-title":"JCO"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103141_b0410","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.18632\/oncotarget.26758","article-title":"Targeting claudin-4 enhances CDDP-chemosensitivity in gastric cancer","volume":"10","author":"Nishiguchi","year":"2019","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103141_b0415","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.3390\/ijms24065494","article-title":"Claudin-4: a New Molecular Target for Epithelial Cancer Therapy","volume":"24","author":"Fujiwara-Tani","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103141_b0420","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1074\/jbc.M109.051417","article-title":"Clostridium perfringens Enterotoxin Interacts with Claudins via Electrostatic Attraction","volume":"285","author":"Kimura","year":"2010","journal-title":"J Biol Chem"},{"issue":"19","key":"10.1016\/j.ctrv.2026.103141_b0425","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.3390\/ijms20194774","article-title":"Use of Modified Clostridium perfringens Enterotoxin Fragments for Claudin Targeting in Liver and Skin Cells","volume":"20","author":"Beier","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103141_b0430","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40164-025-00624-9","article-title":"Development of a bispecific antibody\u2013drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors","volume":"14","author":"Luo","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.ctrv.2026.103141_b0435","article-title":"Abstract 6010: Evaluation of BsABN501: a novel T cell engager targeting CLDN3-positive solid tumors","volume":"85(8_Supplement_1):6010\u20136010","author":"Lee","year":"2025","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103141_b0440","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3390\/ijms21020569","article-title":"Claudin-1, a Double-Edged Sword in Cancer","volume":"21","author":"Bhat","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103141_b0445","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.18632\/oncotarget.2936","article-title":"Claudin-1 enhances tumor proliferation and metastasis by regulating cell anoikis in gastric cancer","volume":"6","author":"Huang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2026.103141_b0450","doi-asserted-by":"crossref","DOI":"10.1038\/s41568-026-00913-3","article-title":"Claudin proteins as emerging therapeutic targets for solid tumours","author":"Saviano","year":"2026","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103141_b0455","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1038\/s41598-021-81667-w","article-title":"PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms","volume":"11","author":"Nakano","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2026.103141_b0460","article-title":"Abstract 2962: ASP2138, a novel 2+1 format, claudin 18.2 x CD3 bispecific antibody, demonstrates selectivity and activity in preclinical cancer models","volume":"83(7_Supplement):2962\u20132962","author":"Nakazawa","year":"2023","journal-title":"Cancer Res"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T02:09:51Z","timestamp":1778292591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":92,"alternative-id":["S0305737226000551"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103141","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting claudins in gastric cancer: A novel GLOWing strategy in the SPOTLIGHT","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103141","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103141"}}